| 000 | 01685 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250514042024.0 | ||
| 264 | 0 | _c20021007 | |
| 008 | 200210s 0 0 fre d | ||
| 022 | _a0399-8320 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLeroy, Vincent | |
| 245 | 0 | 0 |
_a[Evaluation of response to treatment in chronic hepatitis C]. _h[electronic resource] |
| 260 |
_bGastroenterologie clinique et biologique _cApr 2002 |
||
| 300 |
_aB23-31 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Consensus Development Conference; Journal Article; Review | ||
| 650 | 0 | 4 |
_aAlanine Transaminase _xblood |
| 650 | 0 | 4 |
_aAmantadine _xadministration & dosage |
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 | _aBiopsy |
| 650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xepidemiology |
| 650 | 0 | 4 | _aClinical Enzyme Tests |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHepacivirus _xgenetics |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 |
_aInterferons _xadministration & dosage |
| 650 | 0 | 4 |
_aLiver _xpathology |
| 650 | 0 | 4 |
_aLiver Neoplasms _xepidemiology |
| 650 | 0 | 4 | _aMeta-Analysis as Topic |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRNA, Viral _xblood |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 |
_aRibavirin _xadministration & dosage |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTransaminases _xblood |
| 650 | 0 | 4 |
_aViremia _xdiagnosis |
| 700 | 1 | _aHilleret, Marie-Noëlle | |
| 773 | 0 |
_tGastroenterologie clinique et biologique _gvol. 26 Spec No 2 _gp. B23-31 |
|
| 999 |
_c12062794 _d12062794 |
||